Chardan Capital Sticks to Their Buy Rating for Immatics (IMTX)
November 17 2022 - 06:15PM
TipRanks
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on
Immatics (IMTX - Research Report) today and set a price target of
$28.00. The company's shares closed today at $10.26.Livshits covers
the Healthcare sector, focusing on stocks such as Rocket
Pharmaceuticals, Intellia Therapeutics, and Immatics. According to
TipRanks, Livshits has an average return of 25.9% and a 41.91%
success rate on recommended stocks. Immatics has an analyst
consensus of Moderate Buy, with a price target consensus of
$28.00.See the top stocks recommended by analysts >>Based on
Immatics' latest earnings release for the quarter ending June 30,
the company reported a quarterly revenue of $17.
https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-immatics-imtx?utm_source=advfn.com&utm_medium=referral
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From May 2023 to Jun 2023
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Jun 2022 to Jun 2023